Skip to content

Vanessa Fleury

3 papers in the library · 3 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Neural Correlates of Cognitive Alterations and Minor and Structured Hallucinations in Parkinson's Disease

medRxiv July 10, 2026 Lada Kohoutová, Jevita Potheegadoo, Léa F Duong Phan Thanh et al.

Background: Hallucinations, ranging from minor (MH) to structured, are a common non-motor symptom in Parkinson's disease (PD). Structured hallucinations have been associated with altered functional connectivity (FC) between dorsal/ventral attention (DAN, VAN) and default mode (DMN) networks. As structured hallucinations are linked to rapid cognitive decline and MH are often viewed as their...

[Treatment with psychedelics : potential benefits in Parkinson's disease].

Revue medicale suisse April 23, 2025 Louise Penzenstadler, Sandra Baudois, Alma Lingenberg et al.

Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their efficacy has been demonstrated in depression and anxiety, where they are particularly interesting because of their rapid and long-lasting effect. They could also be beneficial for addictions, post-traumatic stress, and obsessive-compulsive disorder. This...

Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.

Journal of Parkinson's disease March 1, 2025 Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé et al. 3 citations

BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant...